Sarcoma: Causes, Symptoms, Treatment and Prognosis — Overview, Diagnosis & Treatment Options | MyMedicPlus

Sarcomas are a heterogeneous group of malignant tumors arising from mesenchymal tissues — the connective tissue that gives rise to bone, cartilage, muscle, fat, blood vessels, nerves, and fibrous tissue. They are broadly divided into soft tissue sarcomas (STS) and bone sarcomas (osteosarcoma, Ewing sarcoma, chondrosarcoma). Approximately 13,000 new cases of STS and 3,500 new cases of bone sarcoma are diagnosed annually in the United States. Over 50 distinct histological subtypes of STS are recognized by the 2020 WHO Classification, each with unique molecular alterations, clinical behavior, patterns of metastasis, and treatment sensitivities — making sarcoma one of the most biologically diverse malignancy categories. The most common STS subtypes include undifferentiated pleomorphic sarcoma (UPS, formerly MFH), liposarcoma (well-differentiated/dedifferentiated and myxoid/round cell), leiomyosarcoma, synovial sarcoma, and gastrointestinal stromal tumor (GIST). Soft tissue sarcomas arise predominantly in the extremities (approximately 50%), retroperitoneum (approximately 15%), trunk/thorax (approximately 15%), and head and neck (approximately 10%). High-grade sarcomas carry a 30-50% risk of distant metastasis, primarily to the lungs.

Most sarcomas arise sporadically without identifiable cause. Prior therapeutic radiation therapy — for breast cancer, lymphoma, gynecological cancers, or other malignancies — is the most clearly established environmental risk factor, causing radiation-associated sarcoma (predominantly angiosarcoma, UPS, or malignant peripheral nerve sheath tumor) with a latency of approximately 10-30 years. Chronic lymphedema from any cause — particularly after breast cancer surgery and axillary lymph node dissection — predisposes to cutaneous angiosarcoma (Stewart-Treves syndrome). Herbicide/dioxin exposure (Agent Orange) has been associated with soft tissue sarcoma in some epidemiological studies. Hereditary cancer syndromes increase STS risk: Li-Fraumeni syndrome (germline TP53 mutations, associated with multiple sarcoma types); NF1 (neurofibromatosis type 1, predisposes to malignant peripheral nerve sheath tumor, MPNST); hereditary retinoblastoma (germline RB1 mutations, secondary sarcoma risk); and familial adenomatous polyposis (associated with desmoid tumors, Gardner syndrome). GIST is associated with NF1 and SDH-deficiency syndromes. Epstein-Barr virus causes EBV-positive smooth muscle tumors in immunocompromised patients.

Soft tissue sarcomas most commonly present as a painless or mildly painful enlarging soft tissue mass. The most important clinical warning sign is a deep soft tissue mass that is larger than 5 cm, increasing in size, or located deep to the muscle fascia — the 'Rule of Twos' used clinically to guide urgent referral and biopsy. Pain, if present at all, is typically mild and non-specific. Approximately 50% of extremity STS are located in the thigh; they may reach considerable size before diagnosis because there is ample surrounding soft tissue to accommodate growth without causing symptoms. Retroperitoneal sarcomas — predominantly liposarcoma and leiomyosarcoma — often grow to very large sizes (sometimes exceeding 20 cm in greatest dimension) before causing abdominal fullness, compression of adjacent bowel or ureter, lower extremity swelling (inferior vena cava compression), or early satiety. GISTs present with abdominal discomfort, early satiety, GI bleeding, or are discovered incidentally. High-grade tumors may ulcerate through the skin or cause local venous compression. Constitutional symptoms (fever, weight loss) are uncommon except in very advanced disease.

MRI with and without gadolinium is the definitive imaging study for extremity and trunk STS: it characterizes tumor compartmentalization, depth, neurovascular involvement, and satellite nodules critical for surgical planning. CT of the chest, abdomen, and pelvis is essential for staging retroperitoneal sarcomas and for detection of pulmonary metastases (the dominant site of distant spread for most STS). FDG-PET/CT adds value in high-grade, locally advanced tumors or when bone or nodal metastasis is clinically suspected. Core needle biopsy is mandatory before any sarcoma treatment; FNA cytology is insufficient for subtype classification. Biopsy must be performed at the treating sarcoma center or with planning for excision of the biopsy track at definitive surgery — improperly placed biopsies contaminate the surgical field, complicate resection, and worsen local control outcomes. All sarcoma specimens require expert pathological review with comprehensive IHC and molecular testing: FISH for MDM2 amplification (well-differentiated/dedifferentiated liposarcoma), SS18-SSX fusion (synovial sarcoma), EWSR1-FLI1 (Ewing sarcoma), KIT/PDGFRA mutations (GIST), SDH IHC (SDH-deficient GIST), and comprehensive genomic profiling for rare subtypes. FNCLCC grade (1-3) is the dominant prognostic factor. AJCC 8th edition TNM staging.

Surgery — wide local excision with histologically negative surgical margins — is the cornerstone of treatment for localized STS. A 1-2 cm margin of normal tissue around the entire tumor circumference is the standard goal, though anatomical constraints may require microscopic margin compromise in exchange for function preservation. Limb salvage is achieved in approximately 90-95% of extremity sarcomas with modern multidisciplinary management. Adjuvant radiotherapy (external beam IMRT or brachytherapy, 50-66 Gy depending on margins) is standard for high-grade STS (Grade 2-3) of the extremity and trunk, reducing local recurrence from approximately 40% to under 15%. Preoperative radiation (50 Gy) is preferred in many centers as it reduces wound complication rates compared to postoperative radiation. For retroperitoneal sarcomas, preoperative radiation (STRASS trial) followed by resection improves local control. Systemic chemotherapy: first-line for advanced or metastatic high-grade STS is doxorubicin (75 mg/m²) ± ifosfamide (9-10 g/m²), with response rates of approximately 20-30% (monotherapy) and 25-40% (combination). Second-line agents: gemcitabine plus docetaxel (particularly for leiomyosarcoma and UPS); trabectedin (preferred for myxoid/round cell liposarcoma and leiomyosarcoma); pazopanib (non-adipocytic STS); eribulin (liposarcoma, leiomyosarcoma). Subtype-specific targeted agents: imatinib for GIST (KIT-mutant); tazemetostat for epithelioid sarcoma; pexidartinib for TGCT; larotrectinib or entrectinib for NTRK-fusion sarcomas; selpercatinib for RET-fusion infantile fibrosarcoma. Immunotherapy has limited activity in STS outside of alveolar soft part sarcoma and undifferentiated pleomorphic sarcoma.

No population-level screening for sarcoma exists. Preventive measures focus on minimizing modifiable risk factors and maximizing early detection in high-risk populations. Radiation oncologists should apply the ALARA (As Low As Reasonably Achievable) principle and use IMRT to minimize doses to surrounding soft tissues when treating other cancers, thereby reducing the long-term risk of radiation-associated sarcoma in cancer survivors. Aggressive management of chronic lymphedema — compression garments, physiotherapy, and surgical lymph node transfer procedures — may reduce the risk of Stewart-Treves angiosarcoma in long-term breast cancer survivors. Patients with Li-Fraumeni syndrome should undergo annual whole-body MRI surveillance (Toronto protocol) to detect soft tissue sarcomas at an early, potentially curable stage. Patients with NF1 should receive regular clinical monitoring of existing neurofibromas, as rapidly enlarging or painful neurofibromas may indicate MPNST transformation and require urgent MRI evaluation. Patients with FAP and Gardner syndrome require desmoid tumor surveillance, as desmoid tumors can cause life-threatening complications even without malignant transformation.

Any soft tissue lump that is larger than 5 cm, located deep to the muscle fascia, or that is growing should be evaluated urgently by a sarcoma specialist or oncology surgeon — these are the three most important clinical red flags for STS. Painlessness does not exclude sarcoma; the majority of STS are painless at presentation. A thigh, groin, or retroperitoneal mass in an adult should not be assumed benign; MRI and specialist referral are needed before any surgical intervention. Critically, a soft tissue mass should never be surgically excised by a non-specialist without imaging and biopsy at a sarcoma center — unplanned 'whoops surgery' contaminates the surgical field, makes definitive re-excision technically difficult, and worsens local control outcomes substantially. Cancer survivors who previously received radiation therapy should alert their oncologist of any new soft tissue mass in or near the radiation field. Individuals with Li-Fraumeni syndrome, NF1, or hereditary retinoblastoma should be enrolled in specialist surveillance programs and report new soft tissue swellings promptly.

Overall 5-year survival approximately 65% (all stages). Low-grade (Grade 1), small, extremity STS: over 80% 5-year survival. High-grade, large, retroperitoneal STS: approximately 30-50%. Metastatic STS: approximately 15-20% 5-year survival. Subtype-specific differences are substantial: GIST (imatinib-treated) and synovial sarcoma have better prognosis; angiosarcoma and MPNST have worse. Molecularly targeted therapies significantly improve outcomes in selected subtype-specific patients. The prognosis for Sarcoma: Causes, Symptoms, Treatment and Prognosis varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.